-
Je něco špatně v tomto záznamu ?
High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells
Š. Šimečková, Z. Kahounová, R. Fedr, J. Remšík, E. Slabáková, T. Suchánková, J. Procházková, J. Bouchal, G. Kharaishvili, M. Král, P. Beneš, K. Souček,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV15-28628A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- antigen CD24 genetika MeSH
- antigeny CD44 genetika MeSH
- buňky PC-3 MeSH
- epitelo-mezenchymální tranzice * MeSH
- lidé MeSH
- myši nahé MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádorové kmenové buňky metabolismus fyziologie MeSH
- nádory prostaty genetika metabolismus patofyziologie MeSH
- proteiny asociované s kinázou S-fáze genetika MeSH
- regulace genové exprese u nádorů * MeSH
- stupeň nádoru MeSH
- xenogenní modely - testy protinádorové aktivity MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Skp2 is a crucial component of SCFSkp2 E3 ubiquitin ligase and is often overexpressed in various types of cancer, including prostate cancer (PCa). The epithelial-to-mesenchymal transition (EMT) is involved in PCa progression. The acquisition of a mesenchymal phenotype that results in a cancer stem cell (CSC) phenotype in PCa was described. Therefore, we aimed to investigate the expression and localization of Skp2 in clinical samples from patients with PCa, the association of Skp2 with EMT status, and the role of Skp2 in prostate CSC. We found that nuclear expression of Skp2 was increased in patients with PCa compared to those with benign hyperplasia, and correlated with high Gleason score in PCa patients. Increased Skp2 expression was observed in PCa cell lines with mesenchymal and CSC-like phenotype compared to their epithelial counterparts. Conversely, the CSC-like phenotype was diminished in cells in which SKP2 expression was silenced. Furthermore, we observed that Skp2 downregulation led to the decrease in subpopulation of CD44+CD24- cancer stem-like cells. Finally, we showed that high expression levels of both CD24 and CD44 were associated with favorable recurrence-free survival for PCa patients. This study uncovered the Skp2-mediated CSC-like phenotype with oncogenic functions in PCa.
Department of Chemistry and Toxicology Veterinary Research Institute Brno Czech Republic
Department of Urology University Hospital Olomouc Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028925
- 003
- CZ-PrNML
- 005
- 20210114155333.0
- 007
- ta
- 008
- 210105s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-019-42131-y $2 doi
- 035 __
- $a (PubMed)30952903
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Šimečková, Šárka $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne´s University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 245 10
- $a High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells / $c Š. Šimečková, Z. Kahounová, R. Fedr, J. Remšík, E. Slabáková, T. Suchánková, J. Procházková, J. Bouchal, G. Kharaishvili, M. Král, P. Beneš, K. Souček,
- 520 9_
- $a Skp2 is a crucial component of SCFSkp2 E3 ubiquitin ligase and is often overexpressed in various types of cancer, including prostate cancer (PCa). The epithelial-to-mesenchymal transition (EMT) is involved in PCa progression. The acquisition of a mesenchymal phenotype that results in a cancer stem cell (CSC) phenotype in PCa was described. Therefore, we aimed to investigate the expression and localization of Skp2 in clinical samples from patients with PCa, the association of Skp2 with EMT status, and the role of Skp2 in prostate CSC. We found that nuclear expression of Skp2 was increased in patients with PCa compared to those with benign hyperplasia, and correlated with high Gleason score in PCa patients. Increased Skp2 expression was observed in PCa cell lines with mesenchymal and CSC-like phenotype compared to their epithelial counterparts. Conversely, the CSC-like phenotype was diminished in cells in which SKP2 expression was silenced. Furthermore, we observed that Skp2 downregulation led to the decrease in subpopulation of CD44+CD24- cancer stem-like cells. Finally, we showed that high expression levels of both CD24 and CD44 were associated with favorable recurrence-free survival for PCa patients. This study uncovered the Skp2-mediated CSC-like phenotype with oncogenic functions in PCa.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antigen CD24 $x genetika $7 D051927
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a epitelo-mezenchymální tranzice $7 D058750
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a antigeny CD44 $x genetika $7 D018960
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši nahé $7 D008819
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a nádorové kmenové buňky $x metabolismus $x fyziologie $7 D014411
- 650 _2
- $a buňky PC-3 $7 D000078722
- 650 _2
- $a nádory prostaty $x genetika $x metabolismus $x patofyziologie $7 D011471
- 650 _2
- $a proteiny asociované s kinázou S-fáze $x genetika $7 D044786
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kahounová, Zuzana $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne´s University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Fedr, Radek $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne´s University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Remšík, Ján $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne´s University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.
- 700 1_
- $a Slabáková, Eva $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
- 700 1_
- $a Suchánková, Tereza $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
- 700 1_
- $a Procházková, Jiřina $u Department of Chemistry and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
- 700 1_
- $a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Kharaishvili, Gvantsa $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Král, Milan $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Beneš, Petr $u Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne´s University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Souček, Karel $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. ksoucek@ibp.cz. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne´s University Hospital Brno, Brno, Czech Republic. ksoucek@ibp.cz.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 5695
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30952903 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114155332 $b ABA008
- 999 __
- $a ok $b bmc $g 1609260 $s 1120105
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 9 $c 1 $d 5695 $e 20190405 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a NV15-28628A $p MZ0
- LZP __
- $a Pubmed-20210105
